Individualized Information Sharing Important in All Stages of Cancer Care
the Cancer Therapy Advisor take:
Appropriate, individualized sharing of information for patients with cancer was determined to be important during treatment, at the time of hospital discharge, and in primary care, according to an article published online in the journal European Journal of Cancer Care.
The authors of this study aimed to explore cancer survivors’ experiences regarding information they were given about potential long-term and late effects of pelvic radiotherapy.
Twenty-eight cancer survivors who had received pelvic radiotherapy for a range of cancers (1-11 years prior to the study) were interviewed. Participants from a larger questionnaire survey of patients treated at another hospital were also interviewed.
Results showed the patients acknowledged the potential ability of information to reassure and inform patients, but also identified its ability to produce undesirable effects or raise anxieties about future problems.
Furthermore, the participants identified the importance of the timing, amount of information provided, and context of their situations—value was also placed on information based on personal experience.
Appropriate, individualized sharing of information for patients with cancer was determined to be important during all stages.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Plastics and Cancer
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer